Talbot Alexis
@DrAlexisTalbot
Followers
831
Following
5K
Media
210
Statuses
3K
Assistant Professor in Immunology Paris #myeloma #MGCS #CART @aphp @HopSaintLouis @institut_IRSL @Univ_Paris @HIPI_inserm @UCSF https://t.co/Hfou5jiToD
San Francisco, California, US
Joined June 2012
🏃♂️💚 Avec le Flambeau de la Vie et l’ @APHP, une course pour sensibiliser au #DonDOrganes ! 10 km de l’hôpital Beaujon ➡️ Bichat ➡️ Lariboisière ➡️ arrivée à Saint-Louis : un relais de solidarité et d’espoir✨ 👉 Parlez-en, chacun peut sauver des vies. #Solidarité #Santé #APHP
0
0
0
📢 New paper out in Ther Adv Hematol! 🧪 Real-world safety of venetoclax in hematologic malignancies using French pharmacovigilance data 🇫🇷 📖 https://t.co/gE9yMN7tW5 👏 Huge thanks to @GendronNico, @DavidMSmadja, @Debureaux_PE, and all the HEGP team for the key contribution!
journals.sagepub.com
Background: Venetoclax is the first representative of a new class of targeted therapy, that inhibits selectively B-cell lymphoma-2 (BCL-2), an anti-apoptotic pr...
0
1
1
Disparition du scientifique et immunologiste israélien Zelig Eshhar, pionnier de l’immunothérapie et considéré comme l'un des "pères" de la technologie des cellules CAR-T pour lutter contre les cancers, redonnant espoir à des milliers de patients dans le monde.
Save the date: Save the date: Zelig Eshhar Memorial Symposium | CAR-T Cells: from Vision to Revolution Wednesday, September 2nd at The David Lopatie Conference Centre on the Weizmann Institute of Science
1
0
4
Thanks @Myeloma_Doc for highlighting our report of the first patient treated with anti-BCMA bispecific for R/R POEMS syndrome with a 20-year history in @Haematologica @APHP @HopSaintLouis @Filiere_MaRIH #POEMS #mmsm
Myeloma Paper of the Day, July 9th, Suggested by Robert Orlowski (@Myeloma_Doc) @DrAlexisTalbot
https://t.co/g8REJY7hno
#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MM #Myeloma #Teclistamab #POEMSsyndrome @CancerWorldmag
0
0
3
Just published! Updated EHA-EMN guidelines for the diagnosis, treatment and follow-up of #MultipleMyeloma! #mmsm
https://t.co/Xfg7vrAcTH
@EHA_Hematology @EMN_EuMMnet @UoATherapeutics
nature.com
Nature Reviews Clinical Oncology - In these Evidence-Based Guidelines, a multidisciplinary panel of experts from the European Hematology Association and the European Myeloma Network provide key...
0
29
80
📢 New publication in Clin Lymphoma Myeloma Leuk! Retreatment with anti-CD38-based combinations in multiple myeloma: real-world insights from the EMMY cohort study. ➡️ Real-life efficacy ➡️ Retreatment strategies ➡️ IFM collaboration 🔗 https://t.co/zzidmy33Km
#mmsm #AntiCD38
0
0
4
Just out! New IMS/ IMWG Definition of High Risk Myeloma. @JCO_ASCO #IMWG25
@Myeloma_Society @IMFmyeloma @NikhilMunshiMD @mvmateos @SagarLonialMD @szusmani @NoopurRajeMD
8
116
301
The On-Body Delivery System redefines care by putting treatment in motion, freeing patients from hospital chairs and giving them the comfort, control, and quality of life they truly deserve! @JCO_ASCO @TheIACH @COMyCongress
1
10
27
#ASCO25 And another one! @JCO_ASCO: 5-yr CARTITUDE-1 results for cilta-cel CAR-T. 97 pts, 6 prior #MMsm lines, treated 2018-2019. All likely would have died; instead, 1/3 alive & well 5 yrs out with no maintenance! 👏 Beginning of the end for #plateauenvy? (cc @ninashah33)
3
20
65
Just published in the @NEJM following Dr. @PerrotAurore 's presentation at #ASCO25 on behalf of the IFM group 🇫🇷 and C. Touzeau. 📢📄 MRD-driven strategy in NDMM, a major step forward for multiple myeloma research. #mmsm #MRD #NDMM #IFM
Presented at #ASCO25: In newly diagnosed myeloma, ASCT showed no benefit over chemotherapy in patients without postinduction measurable residual disease, and tandem ASCT was not more effective than single ASCT in those with postinduction MRD. Full MIDAS phase 3 trial results:
0
1
10
Un test simple et rapide à faire pour ceux qui veulent prendre soins de leur santé par @Institut_cancer
cancer.fr
L’Institut national du cancer sort un nouvel outil ludique et interactif : « Mon test prévention cancers ». Grâce à ce test, chacun peut identifier, dans son quotidien, les comportements à risque et...
0
0
1
By request Our 2 hour ASH abstract session @AaronGoodman33 @ManniMD1 and me and many others We get to the abstracts around 35 mins in So many good ones, including CAR PRISM and AQUILA #ASH24
8
22
147
Maladies rares, faire équipe ! Il reste des places pour la journée annuelle de la Plateforme d'expertise maladies rares Paris Nord sur les collaborations inter-centres experts 🗓️RDV le 13 décembre de 13h30 à 16h40 à @HopRobertDebre @APHP ou en ligne Infos https://t.co/18k2Lni561
0
5
6
Here are my Top 5 #ASH24 @ASH_hematology myeloma abstracts. #ASH24VR Links to the full abstract. My Top 5 are based on new data, clinical impact, & methodology Thread with countdown👇
4
71
203
Real-world data in #MZL are rare and precious. So far: 🇺🇸 @LEOcohort, 🇮🇹NF10, 🇬🇧 HMRN Thanks to @LysaLymphoma's REALYSA, we were able to build the first 🇫🇷 MZL prospective cohort. First results (2018-2021) are published today. More will come. https://t.co/7hY2gma5A4
0
7
16
Dr. @PerrotAurore presenting MIDAS trial. Incorporates MRD testing for the various pathways. MRD adapted consolidation and maintenance. Induction IsaKRD. Med age 59 yrs. #IMS24RF #mmsm
1
12
28
Prochaine RCP nationale "MGCS: Gammapathie monoclonale de signification cutanée" organisée par notre centre constitutif intégré @Filiere_MaRIH avec le centre de ref AmyloseAL le 2/10/2024 à 17h, MP pour plus d'info @univ_paris_cite @HopSaintLouis @SFDermatologie @Hematologie_JLE
0
2
1